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SUMMARY Cicatricial pemphigoid is an autoimmune bullous 
disease characterized by mucous membrane fibrosis with resulting 
scarring, predominantly in the conjunctival and oral mucosa, which 
rarely involves skin changes. The majority of patients present with 
painful erosions or desquamative scarring gingivitis, resulting in 
eating and drinking disorders. Typical ocular lesions include chronic 
scarring conjunctivitis with progressive subconjunctival fibrosis, 
fornix foreshortening and synechia formation between the bulbar 
and palpebral conjunctiva, occasionally resulting in blindness. A 69-
year-old woman was admitted to our Department for intense pain 
and severe burning sensation in the oral cavity, induced by several 
erosions and solitary blisters, lasting for 3 years. She was also 
diagnosed with the right eye symblepharon, lid entropion, trichiasis, 
leukoma and blindness of the right eye. The diagnosis of cicatricial 
pemphigoid was based on clinical picture and histopathology 
combined with immunofluorescence methods, with therapy initiated 
thereupon. Systemic corticosteroid (methylprednisolone) therapy in 
combination with azathioprine proved successful in the treatment of 
oral lesions as well as for stabilization of ocular lesions. Unfortunately, 
the patient was diagnosed in the advanced stage when scarring had 
already occurred. Prompt recognition of cicatricial pemphigoid and 
close patient monitoring are an imperative for the future prognosis of 
the disease. 
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INTRODUCTION 
 Cicatricial pemphigoid (Lever 1942, benign 
mucous membrane pemphigoid, scarring pemphi-
goid) (CP) is a chronic autoimmune subepidermal 
bullous disease, which primarily involves mucous 
membranes, predominantly in the oral cavity and 
eyes, but rarely the skin (1-4). In some patients, 
oral blisters may present as the only manifesta-
tion, but extension of lesions into the pharynx and 
esophagus may cause sore throat and dyspha-
gia. Ocular involvement is believed to occur in 
Acta Dermatovenerol Croat                  2007;15(4):236-242                              CASE REPORT 
237ACTA DERMATOVENEROLOGICA CROATICA
approximately 70% of patients; progressive ocular 
lesions may cause blindness (5). 
 Recent studies have demonstrated that CP is 
not a single entity but a complex disease (2). The 
etiopathology of CP has not yet been completely 
understood but is considered as an autoimmune 
disease, with participation of basement mem-
brane-directed antibodies, thus leading to subepi-
thelial blistering, granulation tissue and inflamma-
tory infiltrate formation in the substantia propria. 
Eosinophils and increased proportion of type I and 
type III collagen have also been demonstrated 
in CP patients (6). Various antibodies have been 
found, such as antibodies against BPAg2 carboxy 
terminal domains, NC16A domain (in proximity to 
the keratinocyte membrane), laminin 5 (adhesion 
molecule which interconnects lamina lucida and 
lamina densa, demonstrable on the dermal portion 
of a salt-split skin), hemidesmosomal integrins a6 
and β4 (7-9).
 Increased susceptibility for the CP develop-
ment may also be related to human leukocyte an-
tigens HLA-DR2, HLA-DR4 and DQw7 genotypes 
(6). There is some evidence that ophthalmic medi-
cations, especially those used for glaucoma, may 
cause CP, or possibly the glaucoma reflects early 
ocular lesions in the course of CP (2). 
 Clinical presentation of CP patients may vary; 
it primarily affects the elderly, predominantly wom-
en. Generally, oral lesions have been reported in 
more than 90% and ocular lesions in 60%-70% 
of cases (2). The majority of patients with CP do 
not present with skin lesions; 25% of CP patients 
present with cutaneous lesions. 
 Ocular cicatricial pemphigoid (OCP) is charac-
terized by a chronic scarring conjunctivitis with pro-
gressive subconjunctival fibrosis, fornix foreshort-
ening and synechia formation between the bulbar 
and palpebral conjunctiva (2,6). The disease may 
initially involve only one eye, with initial unspecif-
ic symptoms, often localized for up to 1-2 years, 
but frequently followed by conjunctival fibrosis, 
sometimes with severe entropion, trichiasis, sym-
blepharon, dry eye syndrome, corneal epithelial 
erosions or ulcerations, keratitis and even blind-
ness (4,6). Thus, OCP may present as a chronic, 
acute or subacute disease with periodic exacerba-
tions of conjunctival inflammation, sometimes with 
lacrimal duct and meibomian duct obstruction and 
goblet cell decay, leading to the development of 
dry eye due to the tear film deficiency. Secondary 
glaucoma is one of the most frequent complica-
tions, coincident in up to 25% of patients (2).
 Oral lesions mostly manifest as scattered 
painful erosions or desquamative gingivitis with 
smooth erosions along the fixed gingival or rarely 
mucosal detachment. Scars may be present, but 
oral blisters are rare (2). Buccal mucosa scarring 
results in chewing and swallowing difficulties (oral 
scarring is less significant than in the OCP). Oral 
alterations may affect the frenulum and the tongue 
or vegetating lesions are occasionally localized in 
the mouth. Other mucosal surfaces such as the 
larynx, esophagus, or genitalia may also be in-
volved with possible adhesion and stricture forma-
tion (2).
 The diagnosis of CP is supported by histopath-
ologic analysis of mucosal or skin lesions, which 
typically show marked inflammation with various 
inflammatory cells, followed by fibrosis and vascu-
lar proliferation in a later stage, as expected in a 
scar (2). Histopathologic examination of an intact 
blister shows subepidermal separation resembling 
a bullous pemphigoid blister. Immunofluorescent 
examination is beneficial only in some patients. 
Moreover, direct immunofluorescence has shown 
to be positive in 50%-60% of cases, displaying 
IgG, C3 and occasionally IgA deposits on the 
basement membrane zone. Routine indirect im-
munofluorescence is positive in less than 50% 
of cases. Therefore, more sophisticated methods 
such as salt-split skin or electron immunomicros-
copy may occasionally prove useful (2).
 Recommended treatment includes systemic 
immunosuppressants and corticosteroids, aiming 
to suppress active inflammation. Therapy is pre-
dominantly successful for cutaneous lesions, but 
less effective in the treatment of ocular and oral 
lesions (2). Alternative systemic CP treatment in-
cludes azathioprine (usually in combination with 
corticosteroids), cyclophosphamide (the most ef-
fective systemic immunosuppressive agent), dap-
sone (suitable for oral lesions and mild OCP), reti-
noids, cyclosporine, etc. (2,10,11).
 Topical therapy usually includes local cortico-
steroids, often in the form of special oral adhesive 
pastes or intralesional triamcinolone acetonide. 
The management of ocular lesions is preferentially 
conducted by an ophthalmologist. Surgical treat-
ment is sometimes indicated, such as for lysis or 
removal of skin adhesions, for correction of scars, 
entropion, trichiasis and other complications (2). 
 Since OCP is a distressing chronic disease, 
its treatment is often difficult, with blindness as 
a feared complication occurring in 20%-60% of 
cases. Unfortunately, most patients are diagnosed 
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in the advanced stage when scarring has already 
occurred. 
 The purpose of this case report is to present 
our patient suffering from CP, and to evaluate clini-
cal features, diagnostic and therapeutic difficulties 
in CP.  
CASE REPORT
 A 69-year-old woman was admitted to our De-
partment for intense pain and severe burning sen-
sation in the oral cavity induced by several ero-
sions and solitary blisters, lasting for 3 years. She 
was also diagnosed with the right eye symblepha-
ron, lid entropion, trichiasis, leukoma and blind-
ness of the right eye. Personal history indicated 
that the patient had noticed lesions on the right 
eye five years before, demonstrating progressive 
course; therefore, she was under constant care of 
an ophthalmologist and was treated surgically on 
several occasions. Azathioprine (Imuran) therapy 
was initiated two years before for a two-year peri-
od, however, without any significant improvement. 
Oral lesions including erosions with subsequent 
scar formation occurred in the oral mucosa and 
bilaterally buccally three years before, resulting in 
severe burning sensation and difficult swallowing. 
The patient had no skin changes whatsoever.
 On admission, clinical features on the right 
eye suggested an advanced phase of CP. The 
patient came to our Department for advanced 
lesions of the oral mucosa and eyes (Figures 1 
and 2). The patient had several erosions on the 
buccal mucosa bilaterally and on the hard palate. 
Ocular status showed amaurosis of the right eye 
in addition to symblepharon. There were several 
oral erosions, partly covered with fibrin deposits 
on buccal and palatine mucous membranes with 
gingival cicatricial formations. 
 Excisional biopsy of oral lesions with direct im-
munofluorescence microscopy of skin biopsies 
and indirect immunofluorescence analysis were 
performed. Histopathologic analysis of mucous 
membranes was nonspecific; there were no ele-
ments to confirm the diagnosis, while direct im-
munofluorescence showed neither IgG nor C3 
deposits. Indirect immunofluorescence showed no 
circulating antibodies. 
 Three weeks later, biopsy was repeated due to 
uncertain findings. Repeat histopathologic analy-
ses of oral mucous membrane lesions showed ac-
antholytic cells, and the underlying dermis showed 
loose neutrophilic infiltrates with erythrocyte ex-
travasation. Stratified squamous keratinized epi-
thelium samples were separated at the basal and 
suprabasal keratinocyte level with few detached 
acantholytic cells marginally, which could histolog-
ically contribute to the diagnosis of CP (Figure 3).
 The following diagnostic and laboratory tests 
were performed during hospital stay: complete 
blood count (CBC) was within the physiological 
range except for slightly increased neutrophil and 
lymphocyte counts; glucose, transaminases, elec-
trophoresis, C3, C4, ANA, total bilirubin, total pro-
tein, creatinine and electrolytes showed normal 
findings; cholesterol and triglyceride levels were 
increased, iron decreased and urine analysis ab-
normal. Urine analysis verified bacterial infection 
(Escherichia coli 106/mL), sensitive to cephalexin. 
Other laboratory findings were also normal (pha-
ryngeal and nasal swabs, oral cavity mycology, 
PPD, hemoccult test); ECG showed left ventricu-
lar strain; abdominal ultrasound was free from sig-
nificant changes.
Figure 1. Ocular manifestations in the patient with 
cicatricial pemphigoid.
Figure 2. Oral lesions in the patient with cicatricial 
pemphigoid.
Lugović et al.       Acta Dermatovenerol Croat
Unrecognized cicatricial pemphigoid     2007;15(4):236-242
239ACTA DERMATOVENEROLOGICA CROATICA
 Ophthalmologist consultation confirmed am-
aurosis of the right eye, VOS +1.0, dsph 1.0, the 
upper and lower fornix of the right eye affected by 
symblepharon, with total corneal keratinization. 
Ocular clinical features suggested an advanced 
stage of CP. As results of the biopsy of oral lesions 
were crucial and supported the diagnosis of CP, 
the disease was diagnosed according to clinical 
and histopathological appearance (immunofluo-
rescence analysis was nonspecific). 
 After consulting an internal medicine specialist, 
administration of cyclophosphamide was planned 
following treatment for urinary tract infection (due 
to the indication and imminent blindness) with 
continuous monitoring of leukocyte count (due to 
the possibility of the most common side effects of 
cyclophosphamide therapy including bone mar-
row suppression, hemorrhagic cystitis as a dose-
dependent adverse effect). Methylprednisolone 
(Medrol) was administered during hospital stay at 
a dose of 60 mg initially, tapered to 48 mg daily at 
discharge. The patient used sage tea and pred-
nisone solution topically for oral cavity lesions. In 
continuation as before hospitalization, antihyper-
tensives and cardiac medications were adminis-
tered per os, in addition to oral antibiotic therapy 
for urinary tract infection (cephalexin for 10 days), 
according to the antibiotic sensitivity report ob-
tained. 
 Following discharge from the hospital, the pa-
tient continued taking methylprednisolone (Me-
drol) 48 mg daily per os with gradual dose reduc-
tion, along with therapy prescribed by the internist, 
used sage tea, triamcinolone acetonide (Volon A 
haftsalbe®), and an oral antimycotic agent (micon-
azole gel, Dactarin) topically for oral cavity lesions. 
Systemic corticosteroid therapy showed no side 
effects. Oral lesions completely resolved with time 
and the eye condition became stable, with the pa-
tient using low doses of systemic corticosteroids 
(methylprednisolone) with azathioprine (Imuran, 
100 mg daily). She has been under constant der-
matologist and ophthalmologist care.
 Due to significant clinical and subjective im-
provement with methylprednisolone and azathio-
prine therapy, we decided not to include cyclo-
phosphamide.
DISSCUSION
 The diagnosis of CP is based particularly on 
clinical features and histopathologic examina-
tion, immunofluorescence methods, or sometimes 
electron immunomicroscopy (which enables dis-
tinguishing CP from other autoimmune diseases 
of the dermoepidermal junction). It is sometimes 
difficult to make a diagnose of CP, especially when 
histopathology results, direct immunofluorescence 
and indirect immunofluorescence are negative, as 
found in approximately half of the patients. Care-
ful evaluation of a patient with CP is essential and 
often requires a multidisciplinary approach, involv-
ing a dermatologist, an ophthalmologist, otorhino-
laryngologist, etc. However, histopathologic ex-
amination, direct immunofluorescence microscopy 
of skin biopsies and indirect immunofluorescence 
are mandatory in all patients (13).
 CP is primarily a disease affecting the elderly 
and the majority of CP patients are female (61%), 
as in our case report (5). In the study by Mess-
mer et al., the mean age of patients with OCP was 
73 years, similar as in the study by Baier et al., 
where the mean age at CP onset was 69 (50-76) 
years (5,13). The most prominent finding in CP 
is involvement of mucosal surfaces. Miziara et 
al. found mucosal bullous lesions in 85%-90%, 
ocular lesions in 66%, nasal lesions in 15%-23%, 
and laryngeal involvement in 8%-21% of CP pa-
tients (14). Baier et al. found oral lesions in 90.9% 
(10/11) and/or conjunctival lesions in 54.5% (6/11), 
less frequently lesions of the larynx (4/11), nasal 
Figure 3. Detached stratified squamous epithe-
lium at the level of dermoepidermal junction; H&E 
staining, X100).
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mucosa (3/11), skin (3/11) or pharynx (1/11) (13). 
Agbo-Godeau et al. found variable skin lesions 
(sometimes involving the lower limb); ocular le-
sions (including two patients with severe lesions 
at onset); and nasal and/or laryngeal involvement 
in 35% (6/17) (frequently involving severe lesions 
with major functional impairment) of patients each 
(12).
 It is sometimes difficult to obtain the correct di-
agnosis, as the histopathologic analysis may be 
nonspecific. Study results revealed specific histo-
pathologic findings (subepidermal detachment) in 
64.7% (11/17) and specific positive direct immu-
nofluorescence in 64.7% (11/17) of patients each, 
and negative indirect immunofluorescence in 70% 
(12/17) of patients (12). Agbo-Godeau et al. found 
negative both histologic and immunofluorescence 
analyses in 11.7% (2/17) of patients; electron im-
munomicroscopy was useful in these cases and 
confirmed the diagnosis in 4 patients (12). Repeat 
biopsies are frequently required to obtain a posi-
tive result, as in case of our patient.
 Oral manifestations of CP may be isolated or 
associated with skin or other mucosal lesions 
(12). Agbo-Godeau et al. found sole oral lesions 
in 35.3% (6/17) and coexisting oral and cutane-
ous, ocular, nasal or anal lesions in 64.7% (11/17) 
of patients, with gingival lesions in 88.2% (15/17) 
of patients. The most prominent oral difficulty is 
occasional pain in oral lesions, potentially inter-
fering with eating and drinking. There is rarely a 
laryngeal or pharyngeal stenosis or life-threaten-
ing complications, potentially with squamous cell 
carcinoma in mucosal scarring. Sometimes, there 
is a severe periodontal disease with oral lesions 
(desquamative gingivitis), isolated or combined 
with lesions on the skin and eyes. Although iso-
lated, oral manifestations are generally well con-
trolled by topical corticosteroids, whereas ocular, 
nasal and laryngeal localizations often require 
more extensive treatment (12). Because of fre-
quent painful oral lesions, patients are referred to 
dentists or periodontists; therefore, the diagnosis 
is often made by dentists. Thus, cooperation be-
tween dental specialists and dermatologists is es-
sential to achieve rapid and definitive diagnosis of 
the disease (4). Skin lesions are troublesome, but 
not as significant as the OCP or oral changes (2).
 As OCP involves chronic progressive cicatriz-
ing alterations with complications, it is often diffi-
cult to treat (7). Mostly, OCP includes sight-endan-
gering manifestations and potentially life-threaten-
ing extraocular CP manifestations. There are fre-
quently various complications, such as entropion, 
recurrent epithelial erosions, corneal ulcers, kera-
titis or corneal perforations. Multiple surgical inter-
ventions are sometimes performed, e.g., entropion 
surgery, tarsorrhaphy, mucous membrane graft-
ing, amniotic membrane transplantation, tectonic 
keratoplasty, keratoprosthesis and enucleation. 
Despite anti-inflammatory therapy, visual loss oc-
curred in 53%, while reading visual acuity could 
only be maintained in 35% of patients (5). The 
crucial problem often lies in the late recognition of 
the disease. Messmer et al. presented 28 patients 
with OCP who had reached advanced stage of the 
disease, i.e. stage III (83%) or stage IV (17%) (5). 
Reduced vision at initial presentation was record-
ed in 38%, ocular lesions in 64% and glaucoma 
in 28% of these CP patients. Life-threatening ex-
traocular manifestations of CP (laryngeal stricture, 
esophageal stricture) were manifested in 2/28 pa-
tients. Messmer et al. showed results of conjunc-
tival or mucosal biopsies in OCP, revealing typical 
immune deposits at the basement membrane zone 
in 80% (12/15) of patients (5). High association 
of OCP with glaucoma and/or anti-glaucomatous 
treatment in patients may indicate an etiological 
factor that yet has to be confirmed. Various clinical 
symptoms often render the diagnosis of CP diffi-
cult, yet thorough history, direct and indirect immu-
nofluorescence microscopy and sometimes HLA-
genotyping are crucial for the accurate diagnosis. 
Whenever persistent conjunctival inflammation is 
present, biopsy and immunohistochemical analy-
sis of conjunctival changes should be performed 
in the diagnosis of OCP (6). 
 With regard to advanced CP stages, which 
often result in irreversible visual loss despite ad-
ministration of immunosuppressive therapy, early 
diagnosis and therapy are needed to prevent com-
plications of OCP (5). OCP management requires 
a multidisciplinary approach intended to optimize 
the care for these patients (7). Treatment of OCP 
includes topical drops or ointments (lubricants, 
corticosteroids, antibiotics, antiglaucomatous 
medication) and local corticosteroids, with sys-
temic immunosuppressive drugs necessary for 
activity control in progressive cases (cyclophos-
phamide, systemic corticosteroids, oral dapsone, 
azathioprine, methotrexate, rarely mycophenolate 
mofetil, daclizumab, intravenous immunoglobu-
lin therapy, etc.). Due to the systemic nature of 
the disease and the poor efficacy of current local 
therapies, systemic immunomodulatory therapy is 
the treatment of choice for controlling the disease 
activity and limitation of its progression (7). Sys-
temic cyclophosphamide with short-term adjunc-
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tive high-dose prednisolone is the preferred treat-
ment for severe and/or rapidly progressing OCP. 
Oral methotrexate therapy is the first-line systemic 
therapy for OCP, especially low-dose methotrex-
ate weekly for mild-to-moderate OCP (7,15). It has 
been demonstrated that treatment of OCP patients 
with methotrexate monotherapy after a mean fol-
low-up of 30.2 months results in conjunctival in-
flammation reduction in 89% to 100% of eyes 
(15). Prevention of conjunctival cicatrization pro-
gression was reported in 72% to 90% of patients, 
maintenance or improvement of visual acuity in 
85% of patients (methotrexate monotherapy), and 
final visual acuity was achieved in 74% of the eyes 
(15). Methotrexate therapy is mostly tolerated well, 
although with the possibility of side effects (the 
most common are gastrointestinal (50%), mostly 
reversible upon dose reduction (78%)) (15). Low-
dose oral methotrexate monotherapy is generally 
highly effective and well tolerated as the first-line 
treatment for OCP (15).
 Oral manifestations in CP are often painful and 
may be isolated or associated with skin changes 
or other mucosal lesions (12). Treatment of pa-
tients with CP depends on the disease severity. 
Thus, isolated oral manifestations are generally 
well controlled by topical corticosteroids while 
ocular, nasal and laryngeal localizations often re-
quire more extensive treatment (12). Appropriate 
therapy should be initiated as soon as possible 
due to uncommon spontaneous remissions and 
treatment limitations in the advanced stages of the 
disease (13). Although mucosal and skin lesions 
responded well to the treatment, OCP frequent-
ly shows a progressive course despite therapy. 
Careful evaluation and diagnosis are essential 
and require a multidisciplinary approach.
CONCLUSION
 Since definitive diagnosis of CP is sometimes 
difficult to make, it is essential to analyze the clini-
cal presentation, histopathologic findings of the 
affected tissue, laboratory results, immunological 
findings, and sometimes electron immunomicros-
copy or HLA-genotype. Treatment of our patient 
with systemic corticosteroids (methylprednisolone) 
in combination with azathioprine was successful 
for oral lesions as well as for stabilization of ocular 
lesions. Unfortunately, the patient was diagnosed 
at the advanced stage when scarring had already 
occurred. This indicates that the timely recognition 
of CP and close monitoring of the patient are im-
perative for the future prognosis of the disease. 
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